Timing and treatment strategies according to SCAI classification in cardiogenic shock.

Autor:	Tarantini G; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy., Masiero G; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy., Thiele H; Department of Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Science, Leipzig, Germany., Iannaccone M; Division of Cardiology San Giovanni Bosco Hospital, ASL Città di Torino, Turin, Italy., Schrage B; Department of Cardiology, University Heart and Vascular Centre Hamburg, Hamburg, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Lübeck/Kiel, Hamburg, Germany., Hassager C; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Woitek F; Department of Internal Medicine and Cardiology, Technische Universität Dresden, Herzzentrum Dresden, University Clinic, Dresden, Germany., Chieffo A; Vita-Salute San Raffaele University, Milan, Italy.; Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy., Møller JE; Cardiac Intensive Care Unit, Heart Center, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.; Department of Cardiology, Odense University Hospital, JB Winsløvvej 4, 5000 Odense, Denmark.
Jazyk:	angličtina
Zdroj:	European heart journal supplements : journal of the European Society of Cardiology [Eur Heart J Suppl] 2023 Dec 13; Vol. 25 (Suppl I), pp. I19-I23. Date of Electronic Publication: 2023 Dec 13 (Print Publication: 2023).
DOI:	10.1093/eurheartjsupp/suad129
Abstrakt:	In patients with cardiogenic shock (CS), particularly those with acute myocardial infarction (AMI), evidence suggests that timely diagnosis and treatment interventions are critical in the prevention of haemo-metabolic compromise. Temporary mechanical circulatory support (tMCS) has shown potential in facilitating revascularization and recovery of patients with acute myocardial infarction cardiogenic shock (AMI-CS). Timing of treatment strategies for CS patients needs to be optimized for use of tMCS devices that are applicable to this heterogeneous patient population. Here, the latest evidence as well as the gaps in knowledge surrounding the role of time in the management of patients with CS is summarized. Competing Interests: Conflict of interest Giuseppe Tarantini has received lecture fees from Edwards Lifesciences, Medtronic, Abbott, Boston Scientifics, Abiomed. Giulia Masiero has nothing to disclose. Alaide Chieffo has received lecture/consultant fees from Abbott, Abiomed, Biosensor, Boston Scientifics, Medtronic, Menarini, Shockwave Medical. Jacob Eifer Møller has received an institutional research grant from Abiomed and Novo Nordic Foundation and lecture honorary from Abbott, Abiomed, Boehringer Ingelheim, and Orion. Christian Hassager has received lecture honorarium from Abiomed and research grants from Novo Nordisk Foundation, Lundbeck Foundation, and the Danish Heart Foundation. Benedikt Schrage has received lecture honorarium from Abbott, Abiomed, and AstraZeneca as well as research grants from Abiomed, the German Research Foundation, the Else Kröner-Fresenius-Stiftung and the University of Hamburg. (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu